Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A medulloblastoma that is characterized as a molecular subtype by activation of the sonic hedgehog (SHH) pathway and TP53 mutations that may be present or absent.
Biomarker and diagnostic research for medulloblastoma SHH activated has been reported in the published literature.
No clinical trials have been registered for medulloblastoma SHH activated.
5 publications have been identified in PubMed for medulloblastoma SHH activated. Research spans Other (20%), Diagnostic / Biomarker (20%), and Review / Meta-Analysis (20%).
Raby M (2026). [PMID: 42098819](https://pubmed.ncbi.nlm.nih.gov/42098819/). *Acta Neuropathol Commun*. [Basic Science / Preclinical]
Zhao Q (2026). [PMID: 41609893](https://pubmed.ncbi.nlm.nih.gov/41609893/). *Discov Oncol*. [Diagnostic / Biomarker]
Marzouki S (2025). [PMID: 39436558](https://pubmed.ncbi.nlm.nih.gov/39436558/). *Acta Neurol Belg*. [Other]
Sivapathasundaram A (2025). [PMID: 41225251](https://pubmed.ncbi.nlm.nih.gov/41225251/). *EJNMMI Rep*. [Review / Meta-Analysis]
Maureille A (2025). [PMID: 40575408](https://pubmed.ncbi.nlm.nih.gov/40575408/). *Neurooncol Adv*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 11:55 PM UTC